OPKO Health (OPK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
OPKO Announces Financial and Operating Results
February 29, 2016 4:16 PM ESTConsolidated Revenue Increased to $276.2 Million From $25.5 Million for the Three Months Ended December 31, 2015, and Increased to $491.7 Million from $91.1 Million for the Year Ended December 31, 2015 Clinical Utility Study Demonstrates 4Kscore® Test Reduces Number of Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer 4Kscore Blood Test to Identify Risk of Aggressive Prostate Cancer Assigned Level 1 CPT Code Rayaldee PDUFA Date Remains on Track For March 29, 2016 Topline Phase 3 Results for hGH-CTP in Adults Expected 2H 2016; Pediatric Phase 3... More
OPKO's GeneDx Recognizes International Rare Disease Day with Donation of Free Exome Tests to Syndromes Without a Name
February 29, 2016 8:30 AM ESTOTSEGO, Mich. and MIAMI, Feb. 29, 2016 /PRNewswire/ -- OPKO Health, Inc. (NYSE: OPK) through its GeneDx subsidiary and Syndromes Without a Name (SWAN) are proud to announce the donation of five Whole Exome Sequencing (WES) Trio tests to SWAN on Rare Disease Day as a way to honor the company's founding principles. Rare Disease Day, which takes place on the last day of February each year, aims to raise awareness about rare and ultra-rare diseases and the impact that they have on patients' lives.
"As a laboratory founded to... More
